Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1976 1
1980 1
1981 2
1983 1
1984 1
1986 2
1987 1
1988 1
1989 1
1991 2
1993 3
1994 2
1996 1
1997 2
1998 5
2000 4
2001 2
2002 3
2003 3
2004 3
2005 3
2006 3
2007 6
2008 4
2009 5
2010 6
2011 7
2012 11
2013 17
2014 8
2015 10
2016 11
2017 11
2018 7
2019 8
2020 11
2021 10
2022 9
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
State-of-the-art evidence in the treatment of systemic sclerosis.
Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. Pope JE, et al. Nat Rev Rheumatol. 2023 Apr;19(4):212-226. doi: 10.1038/s41584-023-00909-5. Epub 2023 Feb 27. Nat Rev Rheumatol. 2023. PMID: 36849541 Free PMC article. Review.
Treatment in SSc, including early diffuse cutaneous SSc (dcSSc) and the use of organ-specific therapies, has improved, as evident from randomized clinical trials. Treatments for early dcSSc include immunosuppressive agents such as mycophenolate mofetil, methotrexate …
Treatment in SSc, including early diffuse cutaneous SSc (dcSSc) and the use of organ-specific therapies, has improved, as evident from ra …
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM. Röth A, et al. Blood. 2022 Sep 1;140(9):980-991. doi: 10.1182/blood.2021014955. Blood. 2022. PMID: 35687757 Free PMC article. Clinical Trial.
Twenty-one (96%) sutimlimab patients and 20 (100%) placebo patients experienced 1 treatment-emergent adverse event. Headache, hypertension, rhinitis, Raynaud phenomenon, and acrocyanosis were more frequent with sutimlimab vs placebo, with a difference of 3 patients …
Twenty-one (96%) sutimlimab patients and 20 (100%) placebo patients experienced 1 treatment-emergent adverse event. Headache, hypertension, …
Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review.
Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Martina E, et al. Toxins (Basel). 2021 Feb 5;13(2):120. doi: 10.3390/toxins13020120. Toxins (Basel). 2021. PMID: 33562846 Free PMC article.
The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey-Hailey disease, epidermolysis bullosa simplex Weber-Cockayne type, Darier's disease, pachyonychia congenita, aquagenic keratoderma, alopecia, pso …
The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey-Haile …
Cryofibrinogenemia.
Michaud M, Pourrat J. Michaud M, et al. J Clin Rheumatol. 2013 Apr;19(3):142-8. doi: 10.1097/RHU.0b013e318289e06e. J Clin Rheumatol. 2013. PMID: 23519183 Review.
Skin manifestations are usually the first signs and are usually moderate; in addition, cold intolerance, Raynaud phenomenon, purpura, or livedo reticularis often occurs. Skin necrosis, acral ulcers, and gangrene can lead to surgery and amputation. ...Compared with c …
Skin manifestations are usually the first signs and are usually moderate; in addition, cold intolerance, Raynaud phenomenon, p …
Recognizing and treating Raynaud phenomenon.
Thoelen K, Maiers K, Bondi KA, Covino J. Thoelen K, et al. JAAPA. 2015 Nov;28(11):40-4. doi: 10.1097/01.JAA.0000471610.61784.da. JAAPA. 2015. PMID: 26501577 Review.
This article describes the clinical presentation of Raynaud phenomenon and how to diagnose and appropriately treat patients and prevent complications. Research on the use of different pharmacologic interventions for Raynaud phenomenon is ongoing …
This article describes the clinical presentation of Raynaud phenomenon and how to diagnose and appropriately treat pati …
Nonarteriosclerotic vascular disease.
Wu W, Chaer RA. Wu W, et al. Surg Clin North Am. 2013 Aug;93(4):833-75, viii. doi: 10.1016/j.suc.2013.04.003. Epub 2013 Jun 17. Surg Clin North Am. 2013. PMID: 23885934 Review.
Raynaud's phenomenon in the occupational context.
Cordeiro RA, Andrade RM. Cordeiro RA, et al. Rev Assoc Med Bras (1992). 2019 Nov 7;65(10):1314-1320. doi: 10.1590/1806-9282.65.10.1314. eCollection 2019. Rev Assoc Med Bras (1992). 2019. PMID: 31721965 Free article. Review.
CONCLUSIO: In general, a higher prevalence of Raynaud's phenomenon was found among vibratory tool operators compared to non-exposed workers, with an increase in the number of cases the higher the level of vibration and the time of exposure. Cold is a triggering and aggravating fa …
CONCLUSIO: In general, a higher prevalence of Raynaud's phenomenon was found among vibratory tool operators compared to non-exposed workers, …
Treating Raynaud phenomenon: Beyond staying warm.
Shapiro SC, Wigley FM. Shapiro SC, et al. Cleve Clin J Med. 2017 Oct;84(10):797-804. doi: 10.3949/ccjm.84a.17025. Cleve Clin J Med. 2017. PMID: 28985172 Free article. Review.
Raynaud phenomenon is an overactive vascular response to cold and emotional stress that results in cutaneous color changes and sensory symptoms in the digits. ...
Raynaud phenomenon is an overactive vascular response to cold and emotional stress that results in cutaneous color changes and …
Scleroderma and Raynaud Phenomenon: The Cold Truth Regarding the Use of Operative Management.
Hakami LM, Forster GL, Jones MK, DeGeorge BR Jr. Hakami LM, et al. Plast Reconstr Surg. 2022 Jul 1;150(1):105e-114e. doi: 10.1097/PRS.0000000000009187. Epub 2022 May 10. Plast Reconstr Surg. 2022. PMID: 35544320
BACKGROUND: Raynaud phenomenon, with and without scleroderma, is a common vasospastic condition that manifests with extremity pain and skin discoloration. ...Secondary outcomes included hospital admissions, upper extremity wounds, and amputation within 1 year of dia …
BACKGROUND: Raynaud phenomenon, with and without scleroderma, is a common vasospastic condition that manifests with extremity …
Raynaud phenomenon.
Porter SB, Murray PM. Porter SB, et al. J Hand Surg Am. 2013 Feb;38(2):375-7; quiz 378. doi: 10.1016/j.jhsa.2012.08.035. Epub 2012 Nov 13. J Hand Surg Am. 2013. PMID: 23158111 Review. No abstract available.
177 results